严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019-20冠状病毒爆发
病毒学
梅德林
倍他科诺病毒
作者
Jerome H. Kim,Florian Marks,John D. Clemens
出处
期刊:Nature Medicine
[Springer Nature]
日期:2021-01-19
卷期号:27 (2): 205-211
被引量:213
标识
DOI:10.1038/s41591-021-01230-y
摘要
After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required. These considerations should include how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, the equitable distribution of vaccines and the logistics of global vaccine delivery, all of which are a prelude to a massive vaccination campaign targeting people of all ages. Furthermore, additional scientific questions about the vaccines remain that should be answered to improve vaccine efficacy, including questions regarding the optimization of vaccination regimens, booster doses, the correlates of protection, vaccine effectiveness, safety and enhanced surveillance. The timely and coordinated execution of these post-efficacy tasks will bring the pandemic to an effective, and efficient, close.
科研通智能强力驱动
Strongly Powered by AbleSci AI